ALNYLAM PHARMACEUTICALS, INC. Income Taxes Paid
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Income Taxes Paid of $14.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-12-31 was $12.71M, a 105.31% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-09-30 was $1.28M, a 72.28% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-06-30 was -$1.87M, a 218.87% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-03-31 was $2.97M, a 49.42% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2025 was $15.09M, a 5.07% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2024 was $14.36M, a 138.50% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2023 was $6.02M, a 126.87% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2022 was $2.65M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.73M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | $12.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $13.99M derived: sum of 2 quarters · filed 2026-02-12 | $12.12M derived: sum of 3 quarters · filed 2026-07-30 | $15.09M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$594.00K derived: sum of 2 quarters · filed 2026-07-30 | $2.38M 10-Q · filed 2025-10-30 | $8.57M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.10M 10-Q · filed 2026-07-30 | $7.29M derived: sum of 3 quarters · filed 2026-07-30 | $11.90M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $2.97M 10-Q · filed 2025-05-01 | $9.16M derived: sum of 2 quarters · filed 2025-05-01 | $13.77M derived: sum of 3 quarters · filed 2025-10-30 | $15.34M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $10.80M derived: sum of 2 quarters · filed 2025-10-30 | $12.37M derived: sum of 3 quarters · filed 2025-10-30 | $14.36M 10-K · filed 2025-02-13 | |
| 2024-09-30 | $4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.18M derived: sum of 2 quarters · filed 2025-10-30 | $8.17M 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $3.56M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $1.99M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | $6.02M 10-K · filed 2025-02-13 | ||||
| 2022-12-31 | $2.65M 10-K · filed 2025-02-13 | ||||
| 2016-12-31 | $111.00K 10-K · filed 2017-02-15 | ||||
| 2015-12-31 | $66.00K 10-K · filed 2017-02-15 | -$66.00K 10-K · filed 2016-02-12 | |||
| 2014-12-31 | -$517.00K 10-K · filed 2017-02-15 | $517.00K 10-K · filed 2015-02-13 | |||
| 2013-12-31 | -$11.00K 10-K · filed 2016-02-12 | ||||
| 2012-12-31 | -$17.00K 10-K · filed 2015-02-13 | ||||
| 2011-12-31 | $10.66M 10-K · filed 2014-02-20 | ||||
| 2010-12-31 | -$5.77M 10-K · filed 2013-02-19 | $5.77M 10-K · filed 2011-02-18 | |||
| 2009-12-31 | -$5.84M 10-K · filed 2012-02-13 | $5.84M 10-K · filed 2011-02-18 | |||
| 2008-12-31 | $2.67M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |